In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Direct comparison of safety and efficacy of 2 rule-out strategies for ami:undetectable levels at presentation vs. combination of 1h-algorithm and undetectable levels at presentation

Session Knowing more about STEMI and non-STEMI

Speaker Maria Rubini Gimenez

Event : ESC Congress 2015

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Non-ST-Elevation Myocardial Infarction (NSTEMI)
  • Session type : Moderated Posters

Authors : M Rubini Gimenez (Basel,CH), R Twerenbold (Basel,CH), K Wildi (Basel,CH), M Wagener (Basel,CH), C Puelacher (Basel,CH), P Hillinger (Basel,CH), S Osswald (Basel,CH), C Mueller (Basel,CH)

Authors:
M. Rubini Gimenez1 , R. Twerenbold1 , K. Wildi1 , M. Wagener1 , C. Puelacher1 , P. Hillinger1 , S. Osswald1 , C. Mueller1 , 1University Hospital Basel, Department of Cardiology - Basel - Switzerland ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 173

Purpose: Addressing the increasingly recognized, yet unmet clinical need for rapid rule-out of acute myocardial infarction (AMI), several novel strategies have been developed. Due to the lack of direct comparisons in the same dataset, selection of the best strategy for clinical practice is challenging. We therefore aimed to directly compare the safety and efficacy of two previously defined strategies: LOD (Undetectable levels of high-sensitivity cardiac troponin (hs-cTn) at presentation) versus the combination of Hs-cTn 1h-algorithm and LOD.

Methods: In a prospective international multicentre diagnostic study enrolling 2213 patients presenting with suspected AMI to the emergency department, the final diagnosis of AMI was adjudicated by two independent cardiologists using all available clinical information including serial hs-cTnT concentrations. Safety was quantified as the negative predictive value (NPV) for AMI in the rule-out zone of the respective rule-out strategies. Efficacy was quantified as the percentage of the overall cohort assigned to the rule-out zone by the respective strategy. Both strategies were applied using the two best-validated hs-cTn assays (hs-cTnT Roche: LOD <5ng/L; 1h-algorithm 0h<12ng/l and Δ0–1h<3ng/l; and hs-cTnI Abbott: LOD <2ng/L; 1h-algorithm 0h <5ng/L and Δ0–1h<2ng/l) to ensure that findings are independent from the hs-cTn assay used. As both strategies should only be applied once ST-elevation MI (STEMI) has been excluded by the initial ECG, STEMI patients were excluded from the analysis.

Results: Acute myocardial infarction was the final diagnosis in 17% of patients. Using hs-cTnT, the safety was very high and comparable with both algorithms (LOD: NPV 99.8%, 95% CI 99.0–100% versus LOD+1h-Algorithm: NPV 99.9%, 95% CI 99.5–100%, p=ns).

Regarding efficacy, LOD allowed rule-out in 24% of patients versus 59% with 1h-algorithm +LOD (p<0.001). Using hs-cTnI, the safety was very high and comparable with both algorithms (LOD: NPV 100%, 95% CI 98.8–100% versus LOD+1h-algorithm: NPV 99.2% (95% CI 98.4–99.6, p=ns). Regarding efficacy, LOD allowed the rule-out in 16% of patients versus 53% with the 1h-algorithm (p<0.001).

Conclusion: Both investigated rule-out strategies allow a safe rule-out of AMI, irrespective of the underlying hs-cTn assay. While LOD has the obvious advantage of allowing rule-out already with the measurement at presentation, the combination of LOD and 1h-algorithm is much more effective and more than doubles the number of patients eligible for rule-out.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are